Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic Melanoma
O. Becquart(Centre Hospitalier Universitaire de Montpellier), B. Guillot(Université de Montpellier), M. Beylot‐Barry(Université de Bordeaux), Bastien Oriano(Hôtel-Dieu de Paris), M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble), Célèste Lebbé(Inserm), J.-P. Arnault(Centre National de la Recherche Scientifique), S. Dalac(CHU Dijon Bourgogne), Thierry Lesimple, Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Henri Montaudié(Hôpital l'Archet), F. Aubin(Centre Hospitalier Universitaire de Besançon), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Raphaël Porcher(Hotel Dieu Hospital), Stéphane Dalle(Hospices Civils de Lyon), Laurent Mortier, P Stoebner(Centre Hospitalier Universitaire de Nîmes), Julie De Quatrebarbes(Centre Hospitalier Annecy Genevois), Florence Brunet-Possenti(Assistance Publique – Hôpitaux de Paris), Brigitte Dréno(Nantes Université)
Cited by 2
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k